Yahoo Finance

Operations: Atea Pharmaceuticals, Inc. has not reported any revenue segments as it is currently a clinical-stage biopharmaceutical company focused on the development of oral antiviral therapeutics for serious viral infections.

Market Cap: $240.48M

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company with a market cap of US$240.48 million, remains pre-revenue as it focuses on developing oral antiviral therapeutics. The recent Phase 2 study results for its hepatitis C treatment regimen demonstrated high efficacy and safety, meeting primary endpoints and paving the way for Phase 3 trials. Despite reporting a net loss of US$34.27 million in Q1 2025, the loss has improved from the previous year. Atea's strong cash position supports its ongoing research efforts and share repurchase program while maintaining financial flexibility to pursue long-term growth opportunities in antiviral therapies.

• Click to explore a detailed breakdown of our findings in Atea Pharmaceuticals' financial health report.

• Learn about Atea Pharmaceuticals' future growth trajectory here.

Chegg

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Chegg, Inc. offers personalized educational support services to students worldwide, focusing on essential academic and career skills, with a market cap of approximately $95.91 million.

Operations: The company's revenue primarily comes from its online retail segment, generating $564.61 million.

Market Cap: $95.91M

Chegg, Inc. faces challenges as it navigates compliance issues with the NYSE due to its share price falling below US$1.00, risking delisting if not rectified in six months. Despite being unprofitable and experiencing declining sales—US$121.39 million in Q1 2025 down from US$174.35 million a year ago—Chegg maintains a cash runway exceeding three years and reduced its debt-to-equity ratio significantly over five years. The company is also exploring strategic alternatives to maximize shareholder value while enhancing its educational offerings with innovative tools like Create and Solution Scout, potentially bolstering user engagement amidst competitive pressures from AI-driven platforms like Google's AIO.

• Click here and access our complete financial health analysis report to understand the dynamics of Chegg.

• Gain insights into Chegg's future direction by reviewing our growth report.

Summing It All Up

• Gain an insight into the universe of 718 US Penny Stocks by clicking here.

• Want To Explore Some Alternatives? These 17 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGS:ALEC NasdaqGS:AVIR and NYSE:CHGG.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com